This finding implies that GnRH-II may be a potential drug to treat prostate cancers, even though high affinity binding of GnRH-II to prostate cancer cells appears to be not due to the expression of a conventional GnRH-II receptor. The gene discussed is GNRHR2; the disease is prostate cancer.